273 related articles for article (PubMed ID: 17766650)
21. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.
Mathijssen RH; van Schaik RH
Eur J Cancer; 2006 Jan; 42(2):141-8. PubMed ID: 16325399
[TBL] [Abstract][Full Text] [Related]
22. Body surface area as a determinant of pharmacokinetics and drug dosing.
Sawyer M; Ratain MJ
Invest New Drugs; 2001 May; 19(2):171-7. PubMed ID: 11392451
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacology of anticancer drugs in the elderly: tools for dose-adjustment].
Tranchand B; Falandry C; You B; Girard P; Ribba B; Tod M; Freyer G
Bull Cancer; 2008 May; 95 FMC Onco():F21-7. PubMed ID: 18511363
[TBL] [Abstract][Full Text] [Related]
24. Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan.
Kouno T; Katsumata N; Mukai H; Ando M; Watanabe T
Jpn J Clin Oncol; 2003 Jun; 33(6):309-13. PubMed ID: 12913086
[TBL] [Abstract][Full Text] [Related]
25. BSA-based dosing and alternative approaches.
Sparreboom A
Clin Adv Hematol Oncol; 2005 Jun; 3(6):448-50. PubMed ID: 16167020
[No Abstract] [Full Text] [Related]
26. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA).
Hunter RJ; Navo MA; Thaker PH; Bodurka DC; Wolf JK; Smith JA
Cancer Treat Rev; 2009 Feb; 35(1):69-78. PubMed ID: 18922643
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic drug monitoring of cancer chemotherapy.
Alnaim L
J Oncol Pharm Pract; 2007 Dec; 13(4):207-21. PubMed ID: 18045780
[TBL] [Abstract][Full Text] [Related]
28. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
[TBL] [Abstract][Full Text] [Related]
29. Dose calculation of anticancer drugs.
Gao B; Klumpen HJ; Gurney H
Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1307-19. PubMed ID: 18798700
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic studies in children with cancer.
Groninger E; Proost JH; de Graaf SS
Crit Rev Oncol Hematol; 2004 Dec; 52(3):173-97. PubMed ID: 15582785
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
32. The Effect of Body Weight and Body Surface Area Correction on the Distribution of the ACT Response to Bolus Doses of Heparin for PTCA.
Ferguson JJ; Fathy Waly HM ; Le D; Thomakos N; Wilson JM
J Invasive Cardiol; 1998 Jul; 10(6):318-322. PubMed ID: 10762807
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacokinetics and therapeutic drug monitoring of anticancer agents].
Marquet P; Rousseau A
Bull Cancer; 2008 Oct; 95(10):903-9. PubMed ID: 19004719
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Li J; Jameson MB; Baguley BC; Pili R; Baker SD
Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
[TBL] [Abstract][Full Text] [Related]
35. The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients.
Hansen J; Stephan JM; Freesmeier M; Bender D; Button A; Goodheart MJ
Gynecol Oncol; 2015 Jul; 138(1):154-8. PubMed ID: 25958318
[TBL] [Abstract][Full Text] [Related]
36. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
37. Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force.
Balis FM; Womer RB; Berg S; Winick N; Adamson PC; Fox E;
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28509433
[TBL] [Abstract][Full Text] [Related]
38. Body surface area for adjustment of drug dose.
Drug Ther Bull; 2010 Mar; 48(3):33-6. PubMed ID: 20200147
[TBL] [Abstract][Full Text] [Related]
39. Tailor-made chemotherapy for cancer patients.
van Warmerdam LJ
Neth J Med; 1997 Jul; 51(1):30-5. PubMed ID: 9260487
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy dosing part I: scientific basis for current practice and use of body surface area.
Kaestner SA; Sewell GJ
Clin Oncol (R Coll Radiol); 2007 Feb; 19(1):23-37. PubMed ID: 17305252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
